Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03554096 · ClinicalTrials.gov registry record · NA
Brain Penetrance of 2-HOBA in Humans
A NA study, sponsored by Metabolic Technologies.
- Completed
- Registry status
- NA
- Development phase
- 3
- Enrollment target
NCT03554096: Completed NA study, sponsored by Metabolic Technologies.
NCT03554096 is a NA study that has completed, run by Metabolic Technologies. The registered enrollment target is 3 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03554096, a NA study, has completed, sponsored by Metabolic Technologies.
- COMPLETED
- Registry status
- NA
- Development phase
- 3 participants
- Enrollment target
Study Summary
The purpose of this study is to confirm that 2-HOBA crosses the blood brain barrier and to compare blood and cerebrospinal fluid levels of 2-HOBA after a single oral dose.
Primary Outcome
Ratio of 2-HOBA concentration in the cerebrospinal fluid to plasma 2-HOBA concentration after oral administration (ng/mL)
Interventions
- DIETARY_SUPPLEMENT 2-HOBA
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2018-05-23 |
| Est. Completion | 2019-02-08 |
| Phase | NA |
What the finished NCT03554096 record still lists
NCT03554096 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 3 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower).
The record links to 0 conditions, and to 1 intervention - of which 2-HOBA is the first listed.
NCT03554096 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03554096 about?
NCT03554096 is a clinical study titled "Brain Penetrance of 2-HOBA in Humans". The purpose of this study is to confirm that 2-HOBA crosses the blood brain barrier and to compare blood and cerebrospinal fluid levels of 2-HOBA after a single oral dose.
What is the current status of trial NCT03554096?
This trial is currently completed. It is a NA study. The enrollment target is 3 participants. The study started on 2018-05-23. Estimated completion is 2019-02-08.
What interventions are being tested in trial NCT03554096?
The interventions under investigation include: 2-HOBA (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT03554096?
This trial is sponsored by Metabolic Technologies, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03554096's enrollment target sits among peer trials
3 1996th of 2000 higher than 4 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI